Zacks Investment Research upgraded shares of Allergy Therapeuti (NASDAQ:AGYTF) from a sell rating to a hold rating in a report released on Wednesday morning.

According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “

Shares of Allergy Therapeuti (NASDAQ:AGYTF) opened at 0.39 on Wednesday. Allergy Therapeuti has a 12 month low of $0.33 and a 12 month high of $0.39. The firm’s 50-day moving average price is $0.39 and its 200-day moving average price is $0.39. The firm’s market capitalization is $231.44 million.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/07/allergy-therapeuti-agytf-upgraded-to-hold-at-zacks-investment-research.html.

Receive News & Stock Ratings for Allergy Therapeuti Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeuti and related stocks with our FREE daily email newsletter.